August 30–31 VC News: Dexterous Robots, Heterogeneous Inference, World Models, Clinical Agents
Gap-fill investment explainers for the Aug 18–28 tape still missing deep pages: Sharpa ~$670M, Callosum $100M seed, Veeda $90M+, Faro $37.3M, Multiplier $6M (Lux/YC asset managers), and Hubble $30M B-II — who uses the products and why these syndicates fit.
August 30–31, 2026 did not drop a fresh US mega-tape. The gap-fill is six deals from Aug 18–28 that still lacked Tracker deep pages after the Aug 25–30 batches: Sharpa ~$670M, Callosum $100M seed, Veeda $90M+, Faro $37.3M, Multiplier $6M (Lux/YC), and Hubble Network $30M.
Unexpected truth: the consequential story this weekend is physical AI + inference economics — dexterous hands in Shanghai, chip routing in London, world models in Toronto — not another consumer-agent valuation print.
This index is for founders and scouts who need those six facts with caveats. Last verified August 31, 2026. It does not rehash Aug 29–30 Palona/HubX or AusperBio.
What this index adds
| Company | Amount | Lead / key | Tracker /fund/ | Why it matters |
|---|---|---|---|---|
| Sharpa | ~$670M / >¥4.5B | Alibaba, Tencent, Meituan, JD, HongShan | none | Hesai founders; Wave hands + DQ robot restaurant |
| Callosum | $100M seed | Atomico; Plural, DCVC, UK Sovereign AI | none | Route each AI task to the right chip |
| Veeda | $90M+ seed | Khosla + Radical | Khosla | Fidler world models; Canada mega-seed |
| Faro | $37.3M B | Merck GHI + S32; GC returning | General Catalyst | 6/10 top pharma; clinical agents |
| Multiplier | $6M seed | Lux + YC | Lux, YC | Asset-manager harnesses (≠ pro-services Multiplier) |
| Hubble | $30M B-II | Seraphim SSIT | YC historical | Satellite BLE; 7 sats on orbit |
Who uses these products (one line each)
- Sharpa — robot OEMs + retail automation (DQ); dexterous Wave hands in mass production.
- Callosum — agentic FS workloads on Cerebras; developers adopting heterogeneous silicon without rewrites.
- Veeda — no named customers yet; target is teams training embodied agents in simulation.
- Faro — six of the ten largest pharma clinical-development orgs (company).
- Multiplier — Mercator, Verso, and peer asset managers needing firm-specific agent evals.
- Hubble — Life360, Tile, TI, InPlay, Samsara partnership surface for BLE asset tracking.
Why these funds wrote the checks (judgment)
| Deal | Likely portfolio fit |
|---|---|
| Sharpa | China platforms buying physical-AI infrastructure after model-only years |
| Callosum | European + sovereign bet that inference routing beats monoculture GPUs |
| Veeda | Khosla/Radical doubling world-model research tickets (Waabi, World Labs adjacency) |
| Faro | Strategic pharma capital + GC continuity into agentic clinical workflows |
| Multiplier | Lux frontier systems + CIO angels who are also buyers |
| Hubble | Seraphim multi-stage SpaceTech: SSVII → SSIT C Share follow-on |
What we skipped
- Perceptron “$21M” — TechCrunch corrected funding details; PitchBook path shows prior $16M and an additional round still closing. Product launch (Isaac 0.5) is real; amount not locked here.
- SiteVue $7.5M, ColibriTD €4M, Arrakis $30M — still thin
/fund/coverage or older July stealth; candidates for a later batch. - Town / General Intuition mega marks — wait for closed disclosures (prior memory).
Read next
- Sharpa ~$670M — dexterous hands
- Callosum $100M — heterogeneous inference
- Veeda $90M+ — world models
- Faro $37.3M — clinical agents
- Multiplier $6M — asset-manager AI
- Hubble $30M — space BLE
Follow Venture Capital Tracker in Google
Add VCT as a preferred source to make our venture-capital coverage easier to find in Google Search.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
